Your session is about to expire
What is Parcopa
CarbidopaThe Generic name of this drug
Treatment SummaryCarbidopa is a medication used to treat nausea in patients who do not respond to the combination therapy of levodopa and carbidopa. It works by blocking an enzyme called aromatic amino acid decarboxylase (DDC). Carbidopa does not cross the blood-brain barrier, so it must be taken with levodopa in order to be effective. Products containing solely carbidopa were first developed by Amerigens Pharmaceuticals Ltd and approved by the FDA in 2014. The combination treatment of carbidopa/levodopa was originally developed by Watson Labs but was approved by the FDA in 1992.
Sinemetis the brand name
Parcopa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sinemet
Carbidopa
1975
299
Approved as Treatment by the FDA
Carbidopa, also called Sinemet, is approved by the FDA for 6 uses which include Symptomatic Parkinson Disease and levodopa-driven nausea and vomiting .Symptomatic Parkinson Disease
Used to treat Symptomatic Parkinson Disease in combination with Levodopa
levodopa-driven nausea and vomiting
manganese intoxication
Used to treat manganese intoxication in combination with Levodopa
carbon monoxide intoxication
Used to treat carbon monoxide intoxication in combination with Levodopa
Parkinsonism post encephalitic
Used to treat Parkinsonism post encephalitic in combination with Levodopa
Parkinson's Disease
Used to treat Parkinson's Disease (PD) in combination with Levodopa
Effectiveness
How Parcopa Affects PatientsCarbidopa is a drug that is often taken with levodopa to treat Parkinson's disease. When taken together, carbidopa helps levodopa enter the brain more easily and increases its effectiveness. Carbidopa also helps levodopa stay in the body longer and reduces the amount of levodopa that is converted to dopamine before it reaches the brain. Taking carbidopa with levodopa has been linked to fewer side effects, such as nausea, and a decrease in the amount of levodopa needed to treat Parkinson's Disease. The effect of carbidopa is not affected by the dose.
How Parcopa works in the bodyCarbidopa blocks an enzyme called DDC from breaking down levodopa. DDC is found in the bloodstream and in the brain, but Carbidopa cannot cross the blood-brain barrier. By blocking the enzyme in the bloodstream, Carbidopa prevents levodopa from being broken down before it can reach the brain, where it can be used to make dopamine.
When to interrupt dosage
The measure of Parcopa is contingent upon the diagnosed condition, including Symptomatic Parkinson Disease, carbon monoxide intoxication and Parkinson's Disease. The amount of dosage fluctuates as per the method of delivery featured in the table beneath.Condition
Dosage
Administration
carbon monoxide intoxication
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Parkinson's Disease
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Symptomatic Parkinson Disease
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
levodopa-driven nausea and vomiting
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Parkinsonism post encephalitic
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
manganese intoxication
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Warnings
Parcopa has two contraindications and should not be administered for the ailments enumerated in the following table.Parcopa ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Carbidopa may interact with Pulse Frequency
Common Parcopa Drug Interactions
Drug Name
Risk Level
Description
Abacavir
Minor
Carbidopa may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetaminophen
Minor
Carbidopa may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Aclidinium
Minor
Carbidopa may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Carbidopa may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Carbidopa may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Parcopa Toxicity & Overdose RiskThe toxic dose of carbidopa in rats has been found to be 4810mg/kg. Animal studies have not shown any negative effects on fertility or development. In case of an overdose, it is recommended to immediately perform gastric lavage and give intravenous fluids. Additionally, continuous monitoring of the heart rate is advised.
Parcopa Novel Uses: Which Conditions Have a Clinical Trial Featuring Parcopa?
Currently, 49 active studies are investigating the potential of Parcopa as a treatment for post-encephalitic Parkinsonism, levodopa-induced nausea and vomiting, and manganese intoxication.Condition
Clinical Trials
Trial Phases
Parkinson's Disease
46 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
carbon monoxide intoxication
0 Actively Recruiting
levodopa-driven nausea and vomiting
0 Actively Recruiting
manganese intoxication
0 Actively Recruiting
Parkinsonism post encephalitic
0 Actively Recruiting
Symptomatic Parkinson Disease
4 Actively Recruiting
Phase 2
Parcopa Reviews: What are patients saying about Parcopa?
5Patient Review
5/6/2014 I'm having a lot of trouble finding this particular medicine, and the generic doesn't work as well. My quality of life has really suffered because of it.
4.7Patient Review
7/4/2009 I was getting this drug through UCB in Georgia, but they sold it. I did well on the medication and would like to know where I can get it through a patient assistant program.
4.3Patient Review
5/3/2009 I haven't experienced any nausea with this tablet form of the medication, which is great. I really like it so far!
3.7Patient Review
5/27/2010 I find this treatment to be helpful.
Patient Q&A Section about parcopa
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Parcopa used for?
"This formulation is a treatment for the signs of Parkinson's sickness or similar indications (for example, unsteadiness, solidness, trouble moving). It is believed that Parkinson's malady is activated by too little of a normally happening substance (dopamine) in the cerebrum."
Answered by AI
Is Parcopa the same as Sinemet?
"Carbidopa and levodopa are also used to treat Parkinson's symptoms caused by carbon monoxide poisoning or manganese intoxication. Parcopa is an extended-release version of carbidopa and levodopa."
Answered by AI
How long does it take for Parcopa to work?
"Vitamins containing iron may interfere with the medication's effectiveness. The active ingredients in Sinemet and Parcopa tablets begin to take effect 30 minutes after ingestion."
Answered by AI